Bruce Decotiis
Allergy & Immunology · Brick, NJNPI 1750494613
Payments from drug & device makers
Across 441 payments — averaging $1466.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$252K
- GSK$166K
- Chiesi USA, Inc.$70K
- Hikma Pharmaceuticals USA$64K
- Regeneron$24K
- Sanofi$17K
- plus $54K from 28 others
Across 3 payments — averaging $224.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$667
- Amgen$6
What the payments were for
- Consulting fees$200%
- Speaking & faculty fees$30,36581%
- Travel & lodging$7552%
- Food & beverage$6,34817%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $251,525 |
| GSK | 69 | $166,073 |
| Chiesi USA, Inc. | 26 | $70,071 |
| Hikma Pharmaceuticals USA | 6 | $63,709 |
| Regeneron | 32 | $23,550 |
| Sanofi | 20 | $17,437 |
| Novartis | 18 | $15,710 |
| Astrazeneca UK Limited | 1 | $15,050 |
| Genentech USA, Inc. | 22 | $10,532 |
| Regeneron Healthcare Solutions, Inc. | 34 | $5,071 |
| Merck | 3 | $4,123 |
| Amgen(2 entities) | 20 | $1,419 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $353 |
| CSL Behring | 18 | $318 |
| AbbVie | 22 | $298 |
| Grifols USA, LLC | 8 | $198 |
| Optinose US, Inc. | 10 | $147 |
| Kaleo, Inc. | 9 | $139 |
| Alk-abello, Inc | 7 | $130 |
| Teva Pharmaceuticals USA, Inc. | 10 | $129 |
| Biocryst US Sales Co., LLC | 7 | $112 |
| Covis Pharma GmbH | 5 | $86 |
| Greer Laboratories, Inc. | 4 | $78 |
| Aimmune Therapeutics, Inc. | 5 | $73 |
| Boehringer Ingelheim | 5 | $70 |
| Incyte Corporation | 3 | $49 |
| Pfizer | 3 | $48 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Phadia US Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$646,664 in reported general payments places this provider in the 95th percentile of 135 allergy & immunology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Arnuity ElliptaFluticasone Furoate | 13 | $4,037 |
| Montelukast Sodium | 37 | $593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArnuity Ellipta | $166,073 | $4,03713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Brick
- Chirag PatelBrick$58K
- Mary GeorgyBrick$10K
- Thu Thu AungBrick$9K
- Edward FernandezBrick$6K
- Ellen SherOcean$2.7M
- Andrew PedinoffSkillman$2.3M
- Patrick PerinTeaneck$589K
- Peter RickettiTrenton$501K
- Jinping GuoMarlton$488K
- Mark WeinsteinBelleville$424K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.